food
drug
administr
fda
respons
ensur
safeti
million
unit
blood
blood
compon
donat
year
unit
state
blood
bank
becom
manufactur
industri
industri
must
conform
high
standard
qualiti
control
requir
compar
pharmaceut
compani
regul
industri
said
david
kessler
md
former
fda
commission
screen
donat
blood
infecti
diseas
transmit
blood
transfus
import
step
ensur
safeti
unit
state
safest
blood
suppli
world
fda
strive
keep
safe
decreas
risk
infecti
diseas
transmiss
regulatori
agenc
continu
updat
requir
standard
collect
process
blood
mention
earlier
import
step
ensur
safeti
screen
donat
blood
infecti
diseas
unit
state
test
infecti
diseas
routin
conduct
unit
donat
blood
test
design
compli
regulatori
requir
tabl
fi
eld
clinic
microbiolog
virolog
focus
molecular
technolog
current
nucleic
acid
test
techniqu
develop
screen
blood
plasma
product
evid
recent
viral
infect
could
miss
convent
serolog
test
time
blood
safeti
procedur
includ
molecular
detect
techniqu
hu
us
food
drug
administr
northeast
region
laboratori
liberti
avenu
jamaica
ny
usa
email
yuanhu
fdahhsgov
fi
cial
support
endors
articl
food
drug
administr
intend
infer
approach
signi
fi
cantli
aid
blood
safeti
reduc
risk
transmiss
seriou
diseas
transfus
chapter
review
current
antigenantibodybas
technolog
molecular
biolog
technolog
publish
regulatori
polici
data
blood
safeti
direct
detect
viral
antigen
viru
speci
fi
c
antibodi
common
tool
diagnosi
viru
infect
past
year
limit
direct
detect
viru
antigen
shortli
viru
infect
virus
releas
antigen
amount
suf
fi
cientli
detect
bodi
antibodymedi
assay
indirect
viru
detect
viru
speci
fi
c
antibodi
eg
immuno
fl
uoresc
assay
enzym
immunoassay
eia
etc
problem
shortli
infect
pathogen
viru
window
period
antibodi
gener
insuf
fi
cient
detect
reduc
window
period
low
detect
direct
nucleic
acid
test
need
applic
molecular
biolog
biolog
biochem
analys
revolution
nucleic
acid
genebas
techniqu
develop
screen
blood
plasma
donat
evid
recent
earlier
viral
infect
might
otherwis
miss
convent
serolog
test
nucleic
acid
test
also
provid
evid
genet
variat
virus
molecular
method
includ
use
nucleic
acid
probe
well
ampli
fi
cationbas
dna
sequencebas
techniqu
increas
number
molecular
diagnost
method
avail
commerci
comparison
classic
method
molecular
biolog
method
superior
term
rapid
speci
fi
citi
sensit
current
nucleic
acid
detect
method
fi
eld
may
group
two
major
class
amplifi
techniqu
pcr
nonamplifi
techniqu
southern
blot
hybrid
amplifi
techniqu
sensit
nonamplifi
techniqu
two
differ
type
amplifi
method
target
ampli
fi
cation
method
signal
ampli
fi
cation
method
target
amplifi
techniqu
includ
pcr
nucleic
acid
sequencebas
ampli
fi
cation
nasba
selfsustain
sequenc
ampli
fi
cation
transcriptionbas
ampli
fi
cation
ta
transcriptionmedi
ampli
fi
cation
tma
strand
displac
ampli
fi
cation
sda
ligas
chain
reaction
lcr
signal
ampli
fi
cation
method
includ
branch
dna
bdna
signal
ampli
fi
cation
cleavagebas
signal
ampli
fi
cation
cycl
probe
technolog
invad
assay
replicas
hybrid
captur
cycl
probe
technolog
cpt
rollingcircl
ampli
fi
cation
rca
insur
safeti
blood
product
import
improv
type
nucleic
acid
test
southern
blot
name
edward
southern
develop
procedur
edinburgh
univers
techniqu
use
detect
speci
fi
c
sequenc
within
mixtur
dna
sizefraction
gel
electrophoresi
transfer
capillari
action
suitabl
membran
block
nonspeci
fi
c
bind
site
nitrocellulos
replica
origin
gel
electrophoresi
experi
allow
hybrid
oligonucleotid
probe
repres
speci
fi
c
dna
sequenc
interest
speci
fi
c
dna
present
blot
combin
label
probe
detect
coelectrophores
dna
fragment
known
molecular
weight
size
hybrid
band
determin
southern
blot
hybrid
technolog
one
major
tool
alreadi
help
clinic
staff
worldwid
interpret
genom
inform
compet
methodolog
includ
situ
hybrid
solut
hybrid
import
clinic
exampl
use
technolog
dna
fi
ngerprint
abil
detect
dna
gene
rearrang
dr
kari
mulli
cetu
corpor
conceiv
polymeras
chain
reaction
singl
techniqu
greater
impact
practic
molecular
biolog
pcr
techniqu
detect
infecti
diseas
agent
extrem
low
level
base
abil
sens
antisens
dna
primer
hybrid
dna
interest
follow
extens
primer
dna
templat
dna
polymeras
reaction
heatdenatur
allow
anneal
primer
anoth
round
extens
lead
multipl
increas
dna
product
therefor
minut
amount
dna
ef
fi
cientli
ampli
fi
ed
exponenti
fashion
result
larger
amount
dna
easili
manipul
includ
critic
control
techniqu
made
quantit
current
level
sensit
detect
limit
low
copi
per
ml
blood
hiv
test
import
clinic
exampl
use
pcr
detect
hiv
hcv
pcr
techniqu
evolv
differ
branch
wide
use
viru
detect
clinic
diagnost
realtim
pcr
taqman
roch
light
cycler
roch
smart
cycler
cepheid
situ
pcr
nestedpcr
nestedr
time
pcr
broadrang
pcr
multiplex
pcr
rtpcr
arbitrarili
primer
pcr
long
pcr
quantit
pcr
realtim
sequenc
technolog
come
soon
detail
detect
past
identi
fi
cation
viral
serotyp
restrict
investig
method
use
antibodi
detect
restrict
fragment
length
polymorph
rflp
realtim
sequenc
technolog
abl
detect
viru
earli
well
obtain
viral
sequenc
microarray
develop
stanford
univers
schena
cowork
earli
medic
applic
microarray
analysi
offer
accur
screen
technolog
allow
hundr
thousand
nucleic
acid
hybrid
reaction
perform
solid
substrat
promis
fast
accur
diagnost
tool
fi
eld
clinic
microbiolog
virolog
appli
infect
safeti
blood
blood
product
abl
screen
presenc
viral
pathogen
match
genet
sequenc
compar
exist
technolog
allow
wider
varieti
speci
fi
c
test
carri
simultan
determin
qualiti
blood
provid
consum
extra
safeti
use
molecular
biolog
protocol
microarray
permit
detect
lower
concentr
microorgan
blood
accur
identi
fi
cation
mani
type
pathogen
contamin
near
futur
progress
expect
applic
microarray
technolog
screen
donat
blood
infecti
agent
provid
vast
inform
ident
bloodborn
pathogen
well
gene
express
pro
fi
le
ensur
safe
blood
suppli
may
need
transfus
import
step
ensur
safeti
screen
donat
blood
infecti
agent
donat
unit
donat
blood
undergo
seri
test
bloodborn
agent
human
immunod
fi
cienci
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
human
tcell
lymphotrop
viru
htlv
htlvii
west
nile
viru
wnv
treponema
pallidum
agent
syphili
test
refer
screen
test
design
detect
mani
infecti
agent
possibl
test
sensit
donor
may
falseposit
result
even
donor
never
expos
particular
infect
order
sort
true
infect
falseposit
test
result
screen
test
reactiv
may
follow
speci
fi
c
test
call
con
fi
rmatori
test
thu
con
fi
rmatori
test
help
determin
whether
donor
truli
infect
one
test
fail
affect
blood
product
consid
unsuit
transfus
nucleic
acid
test
nat
employ
test
technolog
directli
detect
genom
virus
nat
detect
viru
genet
materi
instead
wait
bodi
respons
format
antibodi
mani
current
test
offer
opportun
reduc
window
period
infect
agent
undetect
tradit
test
thu
improv
blood
safeti
nat
becom
gold
standard
greater
sensit
compar
antibodi
test
sinc
nat
approv
fda
use
detect
hcv
technolog
current
investig
detect
infecti
diseas
agent
know
mani
viral
infect
viral
rna
appear
earli
infect
week
antibodi
appear
week
eg
hiv
hcv
order
virtual
prevent
infect
transfus
associ
virus
need
detect
virus
window
period
nat
genebas
test
method
need
nat
also
provid
opportun
viral
eg
hiv
hcv
infect
donor
seek
earli
treatment
hand
nat
sensit
method
also
rapid
method
suitabl
blood
bank
laboratori
turnaround
time
maintain
blood
donat
extrem
critic
hbv
highli
infecti
often
nonsymptomat
viru
transmit
primarili
blood
bloodderiv
fl
uid
lead
caus
liver
infect
worldwid
world
health
organ
estim
two
billion
peopl
worldwid
infect
hbv
peopl
chronic
infect
chronic
infect
result
high
risk
liver
cancer
cirrhosi
liver
caus
death
year
year
peopl
becom
newli
infect
unit
state
alon
sinc
begin
screen
hbv
rate
infect
blood
transfus
greatli
decreas
howev
hbv
still
transmit
blood
transfus
unit
blood
one
reason
current
avail
blood
screen
technolog
detect
core
antibodi
surfac
antigen
appear
week
infect
serolog
test
hbv
includ
hepat
b
surfac
antigen
hbsag
hepat
b
core
antibodi
hbcab
hbv
mainli
infect
liver
inner
core
outer
envelop
surfac
hbsag
test
detect
outer
envelop
identifi
individu
infect
hbv
viru
caus
fl
ammat
liver
earliest
stage
diseas
infect
peopl
may
feel
ill
even
yellow
discolor
skin
eye
condit
known
jaundic
fortun
patient
recov
complet
test
neg
hbsag
within
month
ill
small
percentag
peopl
becom
chronic
carrier
viru
case
test
may
remain
posit
year
chronic
infect
peopl
develop
sever
liver
diseas
time
pass
need
follow
care
experienc
physician
reduc
occurr
posttransfus
hepat
essenti
screen
blood
donat
hbsag
sensit
speci
fi
c
assay
blood
donat
found
reactiv
hbsag
test
automat
con
fi
rmed
hbsag
con
fi
rmatori
assay
specimen
neutraliz
con
fi
rmatori
test
specimen
consid
posit
hbsag
hbsag
test
donat
blood
begun
tabl
current
blood
donor
screen
hbsag
occasion
transmiss
hbv
still
occur
due
inclus
window
period
donat
ie
blood
recent
infect
donor
antibodi
neg
still
virem
detect
earli
hbv
infect
blood
donor
still
major
problem
blood
transfus
current
thirdgener
licens
hbsag
test
mostli
radioimmunoassay
enzym
immunoassay
detect
hbv
window
period
hbv
infect
strong
motiv
introduc
molecular
detect
techniqu
fi
eld
commerci
avail
test
method
detect
hbv
dna
market
chiron
quantiplex
hbv
dna
digen
hybrid
captur
abbott
hbv
dna
assay
roch
amplicor
hbv
monitor
use
commerci
hybrid
pcrbase
assay
hbv
dna
detect
week
appear
hbsag
chronic
infect
patient
lost
hbsag
remain
hbv
dna
posit
disquali
fi
ed
potenti
blood
donor
molecular
detect
hbv
dna
sensit
current
method
employ
hbsag
screen
determin
antibodi
hepat
b
core
antigen
antihbc
total
also
use
monitor
progress
hepat
b
viral
infect
determin
antihbc
igm
employ
distinguish
acut
hepat
b
infect
chronic
infect
antihbc
test
develop
detect
antibodi
hbv
produc
infect
individu
posit
antihbc
test
hbsag
test
neg
may
mean
person
hepat
b
recov
infect
individu
posit
test
antihbc
mani
expos
hbv
thu
frequent
problem
fals
posit
although
individu
may
perman
defer
donat
blood
unlik
person
health
neg
affect
note
antibodi
produc
follow
vaccin
hepat
b
hcv
member
flavivirida
famili
virus
associ
human
anim
diseas
hepat
caus
hcv
common
chronic
bloodborn
infect
unit
state
four
million
american
believ
infect
hcv
also
transmit
blood
transfus
hcv
caus
fl
ammat
liver
expos
viru
develop
chronic
infect
lead
liver
fl
ammat
cirrhosi
cancer
death
eventu
peopl
hcv
may
develop
cirrhosi
liver
sever
liver
diseas
form
hepat
individu
may
infect
viru
may
realiz
carrier
sinc
symptom
risk
seriou
ill
peopl
hcv
need
follow
close
physician
experi
evalu
infect
sinc
fi
rst
clone
fulllength
hcv
cdna
signi
fi
cant
progress
made
character
molecular
biolog
natur
histori
hcv
infect
still
larg
unclear
current
treatment
option
patient
limit
vaccin
hcv
avail
treatment
combin
alpha
interferon
ribavirin
ef
fi
caciou
minor
patient
life
cycl
hcv
poorli
understood
due
lack
ef
fi
cient
cell
cultur
system
urgent
need
develop
highli
sensit
detect
method
studi
possibl
extrahepat
site
replic
hcv
recent
establish
cell
cultur
system
replic
hcv
use
human
b
leukemia
cell
line
model
repres
valuabl
tool
detail
studi
initi
step
hcv
replic
cycl
evalu
antivir
molecul
current
appropri
vaccin
strategi
hcv
develop
earli
detect
prevent
hcv
infect
import
blood
safeti
formid
task
design
primer
probe
sensit
nucleic
acid
level
diagnost
assay
throughout
open
read
frame
hcv
genom
high
mutat
rate
genom
region
howev
untransl
region
nucleotid
contain
highli
conserv
domain
allow
stabl
primer
design
qualit
quantit
diagnost
test
equival
sensit
known
six
variou
genotyp
hcv
fi
rst
speci
fi
c
test
hcv
major
caus
nona
nonb
hepat
introduc
third
gener
elisa
kit
avail
detect
antibodi
hcv
screen
blood
hcv
antibodi
recommend
assay
base
detect
serum
antibodi
variou
hcv
antigen
antibodi
nearli
univers
present
patient
chronic
infect
hcv
hcv
screen
test
known
signi
fi
cant
limit
posit
sampl
test
hcv
con
fi
rmatori
test
guidelin
provid
cdc
recommend
hcv
antibodi
screen
test
posit
sampl
con
fi
rmed
serolog
nucleic
acid
supplement
test
hcv
con
fi
rmatori
test
includ
recombin
immunoblot
assay
sever
recombin
peptid
antigen
appli
strip
probe
patient
serum
way
respons
individu
antigen
recogn
falseposit
elisa
result
elimin
eg
riba
chiron
hcv
pcr
assay
eg
roch
coba
amplicor
hcv
test
version
laboratori
choos
perform
test
posit
specimen
base
screen
test
posit
signal
cutoff
ratio
posit
predict
valu
sco
vari
depend
preval
infect
popul
screen
hcv
antibodi
gener
detect
least
week
may
appear
sever
month
acut
hcv
infect
rel
rare
among
blood
donor
antibodi
test
often
fail
detect
patient
window
period
time
infect
time
appear
antibodi
detect
assay
high
sensit
detect
hcv
window
period
longterm
technic
challeng
fi
eld
test
hcv
rna
genom
detect
base
pcr
highli
sensit
rna
detect
system
use
diagnosi
acut
hepat
sensit
detect
hcv
rna
base
rtpcr
nucleic
acid
ampli
fi
cation
techniqu
readili
accomplish
kit
avail
commerci
exampl
fda
approv
roch
amplicor
monitor
ultra
sensit
quantit
assay
measur
hiv
level
copiesml
anoth
commerci
kit
lcx
hiv
rna
quantit
assay
abbott
laboratori
also
detect
limit
copiesml
studi
even
show
sensit
limit
copi
fact
qualit
assay
much
sensit
quantit
assay
hivhcv
screen
sensit
qualit
hcv
molecular
detect
assay
possibl
interdict
virtual
prevent
transfusionassoci
hivhcv
current
sensit
standard
clinic
diagnost
copiesml
sinc
improv
technolog
would
time
chang
sensit
standard
copiesml
andor
viru
caus
acquir
immunod
fi
cienci
syndrom
aid
test
design
detect
antibodi
direct
antigen
virus
much
common
unit
state
wherea
preval
western
africa
donor
test
virus
transmit
infect
blood
case
identi
fi
ed
us
resid
fi
rst
bloodscreen
eia
test
detect
hiv
licens
quickli
implement
blood
bank
protect
blood
suppli
test
donor
blood
antibodi
implement
hiv
antigen
test
donat
blood
mandat
antigen
test
go
compar
pcrbase
test
abil
detect
hiv
window
period
htlv
retrovirus
endem
japan
caribbean
rel
uncommon
unit
state
caus
adult
tcell
leukemialymphoma
neurolog
disord
similar
multipl
sclerosi
infect
persist
lifetim
rare
caus
major
ill
peopl
infect
rare
instanc
viru
may
mani
year
infect
caus
nervou
system
diseas
unusu
type
leukemia
htlvii
infect
usual
associ
intraven
drug
usag
especi
among
peopl
share
needl
syring
diseas
associ
htlvii
hard
con
fi
rm
viru
may
caus
subtl
abnorm
immun
lead
frequent
infect
rare
case
neurolog
diseas
humantlymphotropicvirusantibodi
test
donat
blood
begun
blood
routin
screen
antibodi
htlviii
test
screen
antibodi
direct
epitop
htlviii
virus
sever
commerci
assay
base
enzymelink
immunosorb
assay
elisa
particl
agglutin
format
use
screen
htlv
antibodi
follow
con
fi
rmatori
assay
use
western
blot
infect
individu
serolog
respons
htlv
infect
low
problem
solv
applic
pcr
ampli
fi
cation
speci
fi
c
sequenc
viru
genom
pcr
use
detect
htlviii
provirus
method
choic
detect
htlv
dna
directli
blood
mani
tissu
commerci
pcr
kit
htlv
avail
wnv
singlestrand
rna
viru
flavivirida
famili
recent
emerg
infecti
diseas
threat
public
health
potenti
safeti
blood
suppli
wnv
identi
fi
ed
transfus
transmiss
transmit
mosquito
bird
anim
mosquito
bite
viru
infect
peopl
hors
mani
type
bird
anim
wnv
shown
transmiss
blood
estim
mean
risk
outbreak
region
unit
state
common
symptom
transfusiontransmit
case
wnv
fever
headach
detect
wnv
includ
either
measur
wnv
antibodi
wnv
nucleic
acid
detect
genet
materi
viru
two
type
wnv
antibodi
test
igm
igg
individu
igm
antibodi
present
within
day
initi
exposur
wnv
follow
igg
product
sever
week
later
antibodi
test
detect
wnv
expedi
donor
blood
screen
nat
involv
amplifi
measur
wnv
genet
materi
detect
presenc
viru
blood
tissu
wnv
nat
neg
blood
clinic
ill
occur
situat
nat
igm
antibodi
test
may
need
nucleic
acid
test
screen
blood
wnv
commerci
avail
current
use
viral
yield
wnv
infect
much
lower
virus
consequ
sensit
wnv
nat
system
donor
blood
screen
requir
could
reduc
risk
transfus
transmit
wnv
serum
sampl
blood
unit
subject
either
vener
diseas
research
laboratori
vdrl
test
treponem
test
pallidum
haemagglutin
tpha
test
transfus
unit
found
posit
discard
per
standard
safeti
procedur
test
done
detect
evid
infect
spirochet
caus
syphili
blood
center
began
test
shortli
world
war
ii
syphili
rate
gener
popul
much
higher
risk
transmit
syphili
blood
transfus
exceedingli
small
case
recogn
countri
mani
year
infect
rare
blood
donor
spirochet
fragil
unlik
surviv
blood
storag
condit
sensit
speci
fi
citi
serolog
test
vari
depend
type
test
perform
stage
diseas
donor
spirochetemia
serolog
test
usual
neg
donor
antibodi
posit
blood
infecti
syphili
serolog
test
donor
less
clinic
signi
fi
canc
nucleic
acid
test
accur
detect
syphili
need
use
determin
whether
blood
donor
current
recent
infect
spirochet
recent
year
numer
infecti
agent
found
worldwid
identi
fi
ed
potenti
threat
blood
suppli
among
sever
newli
discov
hepat
virus
present
uniqu
challeng
assess
possibl
risk
even
hepat
viru
test
neg
known
ae
hepat
agent
unidenti
fi
ed
hepat
virus
call
non
ae
hepat
virus
still
transmit
blood
transfus
futur
advanc
nat
may
allow
rapid
discoveri
unknown
hepat
virus
hepat
delta
viru
hdv
small
rna
viru
infect
individu
hbv
worldwid
million
peopl
coinfect
hdv
clinic
import
gener
make
hbv
infect
damag
liver
increas
understand
molecular
virolog
hdv
identifi
novel
therapeut
target
sever
form
chronic
viral
hepat
pcr
realtim
pcr
method
avail
hdv
rna
detect
tt
viru
ttv
name
patient
fi
rst
isol
nona
g
posttransfus
hepat
japan
newli
discov
transfus
transmit
singlestrand
circular
dna
viru
ttv
nonenvelop
entir
sequenc
kb
determin
also
often
interpret
transfusiontransmit
viru
least
genotyp
identi
fi
ed
ttv
found
world
ttv
infect
sought
detect
ttv
dna
serum
polymeras
chain
reaction
use
primer
gener
conserv
region
ttv
genom
eg
utr
region
donor
blood
blood
product
screen
ttv
dna
use
pcr
realtim
pcr
signi
fi
canc
posit
fi
nding
still
unclear
high
level
ttv
carrier
healthi
popul
current
found
whether
ttv
actual
caus
hepat
remain
determin
cytomegaloviru
cmv
viru
belong
herp
group
rare
transmit
blood
transfus
donor
blood
routin
test
cmv
preval
cmv
antibodi
rang
popul
blood
contamin
cmv
caus
problem
neonat
immunocompromis
patient
also
remain
major
pathogen
solidorgan
transplant
recipi
caus
febril
syndrom
hepat
pneumon
retin
coliti
potenti
problem
select
patient
popul
prevent
transfus
cmv
neg
blood
frozen
deglycerol
red
blood
cell
serolog
test
antibodi
cmv
use
determin
whether
patient
cmv
infect
past
determin
great
clinic
import
organ
blood
donor
pretranspl
evalu
prospect
transplant
recipi
commerci
nat
kit
avail
cmv
includ
amplicor
pcr
cmv
monitor
test
hybrid
captur
system
cmv
dna
test
sensit
screen
test
malaria
neither
commerci
avail
fi
cialli
approv
yet
effect
way
screen
donor
take
proper
histori
malaria
fever
could
due
malaria
donor
select
criteria
design
exclud
potenti
infecti
individu
donat
red
blood
cell
transfus
practic
laboratori
test
avail
test
donor
blood
donor
travel
high
risk
malaria
area
exclud
donat
blood
month
howev
need
develop
suitabl
screen
test
especi
use
endem
area
number
clinic
research
approach
develop
extract
ampli
fi
cation
detect
malaria
parasit
dna
blood
product
variant
creutzfeldtjakob
diseas
vcjda
rare
fatal
brain
infect
fi
rst
describ
unit
kingdom
vcjd
strongli
link
exposur
bovin
spongiform
encephalopathi
bse
agent
bse
transmiss
spongiform
encephalopathi
tse
affect
cattl
fi
rst
report
uk
differ
clinic
patholog
characterist
classic
vcjd
diseas
also
particular
genet
pro
fi
le
prion
protein
gene
recent
year
question
rais
concern
potenti
risk
vcjd
diseas
recipi
plasmaderiv
clot
factor
includ
unit
state
licens
factor
eight
pdfviii
factor
nine
pdfix
plasmaderiv
product
immun
globulin
albumin
past
year
report
case
probabl
vcjd
transmiss
red
blood
cell
transfus
unit
kingdom
prion
infect
associ
long
clinic
silent
incub
number
asymptomat
individu
vcjd
prion
infect
unknown
pose
risk
other
blood
transfus
blood
product
organ
tissu
graft
contamin
medic
instrument
order
decreas
risk
need
establish
bloodbas
molecular
assay
detect
vcjd
prion
infect
recent
research
paper
shown
sensit
detect
method
avail
vcjd
prion
howev
commerci
detect
kit
yet
avail
dengu
viru
denv
member
viru
famili
flavivirida
transmit
peopl
bite
infect
mosquito
dengu
viru
shown
four
subtyp
subtyp
differ
strain
dengu
viru
homolog
dengu
emerg
worldwid
problem
sinc
onethird
world
popul
live
area
risk
transmiss
dengu
infect
lead
caus
ill
death
tropic
subtrop
accord
cdc
mani
million
peopl
infect
yearli
dengu
caus
one
four
relat
virus
transmit
mosquito
yet
vaccin
prevent
denv
infect
effect
protect
measur
avoid
mosquito
bite
healthcarerel
transmiss
includ
transmiss
blood
product
dengu
infect
virem
phase
last
day
blood
collect
phase
may
infect
transfus
suscept
host
current
test
direct
detect
dengu
viru
howev
commerci
elisa
test
detect
antibodi
dengu
viru
blood
sampl
patient
recent
research
paper
shown
pcr
detect
method
avail
dengu
viru
strain
babesia
protozoan
parasit
blood
caus
hemolyt
diseas
known
babesiosi
babesiosi
malarialik
parasit
diseas
speci
babesia
identi
fi
ed
unit
state
babesia
microti
agent
commonli
report
caus
human
infect
clinic
confus
human
babesiosi
malaria
often
report
literatur
babesia
infect
also
acquir
blood
transfus
fact
mani
case
transfusioninduc
babesiosi
document
risk
develop
clinic
infect
increas
elderli
asplen
immunosuppress
patient
current
standard
issu
american
associ
blood
bank
aabb
requir
ind
fi
nite
deferr
blood
donor
histori
babesiosi
need
develop
method
identi
fi
cation
b
microti
order
reduc
risk
transmiss
babesiosi
transfus
diagnosi
depend
upon
fi
nding
parasit
blood
fi
lm
examin
detect
week
tick
bite
hamster
inocul
serolog
also
use
diagnosi
indirect
fluoresc
antibodi
test
ifat
avail
b
microti
use
serolog
test
earli
diagnosi
also
pcr
screen
test
babesiosi
technic
avail
fi
eld
chaga
diseas
name
brazilian
physician
carlo
chaga
discov
diseas
chaga
diseas
spread
mainli
bloodsuck
insect
infect
trypanosoma
cruzi
chaga
diseas
also
spread
blood
transfus
organ
transplant
mother
unborn
child
nation
screen
blood
suppli
institut
earli
fda
donor
cruzi
infect
identi
fi
ed
within
past
year
test
screen
cruzi
import
safeti
measur
help
protect
blood
suppli
help
prevent
spread
chaga
diseas
say
karen
midthun
md
act
director
fda
center
biolog
evalu
research
current
serolog
elisa
test
avail
diagnos
chronic
chaga
diseas
pcr
test
tool
diagnosi
chronic
chaga
diseas
clinic
practic
yet
although
research
result
show
pcr
sensit
parasitolog
test
chaga
diseas
activ
transmiss
region
studi
need
develop
molecular
method
coronaviru
rna
viru
known
associ
respiratori
diseas
sever
acut
respiratori
syndrom
sar
newli
recogn
coronaviru
whose
genom
sequenc
belong
known
coronaviru
group
quickli
spread
world
asia
evid
infect
transmit
blood
donor
transfus
recipi
viru
associ
sar
present
blood
peopl
sick
possibl
viru
could
present
blood
immedi
person
get
sick
individu
infect
symptom
possibl
could
transmit
sar
blood
donat
help
determin
whether
individu
might
infect
sar
blood
collect
facil
ask
potenti
donor
oral
write
travel
sarsaffect
countri
histori
sar
possibl
exposur
sar
enzymelink
immunoassay
detect
speci
fi
c
igg
igm
antibodi
rtpcr
detect
sar
coronaviru
speci
fi
c
rna
sar
patient
develop
rapid
sensit
speci
fi
c
identi
fi
cation
sar
novel
coronavirus
molecular
method
import
futur
base
past
histori
hypothet
risk
mani
peopl
infect
unrecogn
virus
exampl
mani
patient
symptom
non
ae
g
ttv
posttransfus
hepat
still
possibl
unexplain
case
posttransfus
hepat
may
caus
new
undiscov
pathogen
recent
year
numer
new
infecti
agent
found
worldwid
identi
fi
ed
timeconsum
procedur
time
new
viru
hcv
hiv
sar
found
mani
peopl
infect
could
larg
number
fatal
urgent
need
develop
method
rapid
identi
fi
cation
character
previous
unknown
pathogen
virus
recent
technolog
detect
identifi
previous
unrecogn
pathogen
express
librari
screen
represent
differ
analysi
rda
broadrang
polymeras
chain
reaction
brpcr
timeconsum
approach
new
unrecogn
uncharacter
viral
agent
rapid
identi
fi
ed
new
molecular
approach
eg
subtract
hybrid
dna
microarray
ensur
safeti
ef
fi
caci
blood
blood
product
critic
regulatori
challeng
high
safeti
level
blood
suppli
result
continu
improv
blood
donor
screen
test
achiev
introduc
updat
nucleic
acid
test
fi
eld
blood
safeti
nat
method
test
blood
sensit
speci
fi
c
convent
test
requir
presenc
antibodi
trigger
posit
test
result
also
nat
work
detect
low
level
viral
genet
materi
present
infect
occur
bodi
develop
immun
respons
viru
improv
sensit
enabl
us
signi
fi
cantli
decreas
infect
window
period
allow
earlier
detect
infect
diminish
chanc
transmiss
agent
via
transfus
protect
blood
suppli
known
pathogen
also
emerg
new
unrecogn
uncharacter
infecti
agent
nat
method
sensit
speci
fi
c
compar
nonnat
futur
nat
technolog
pcr
may
allow
routin
screen
donor
known
unknown
pathogen
concern
blood
safeti
